Company news
Otsuka Holdings Co., Ltd. (TSE:4578) news
Otsuka Holdings Co., Ltd. news releases on 6ix. Latest, Oct 7, 2026: Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA)…
Press releases & updates
Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA) for Traditional Approval of VOYXACT in U.S.
October 7, 2026
NDA Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA RTOR Program
October 1, 2026
Notice regarding the status of share repurchases
October 1, 2026
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
September 18, 2026
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median PFS Benefit in Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation NSCLC
September 13, 2026
Zipalertinib Plus Chemotherapy Meets Primary PFS Endpoint in Planned Interim Analysis of Phase 3 REZILIENT3 Trial
August 12, 2026
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
August 3, 2026
Consolidated Financial Results for the Six-Month Period Ended June 30, 2026 [IFRS]
July 31, 2026
Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2026
July 27, 2026
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
July 24, 2026
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results for VOYXACT in IgAN
July 1, 2026
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT Preserved Kidney Function Over 12 Months in IgA Nephropathy
June 4, 2026
Notice regarding the status of share repurchases
June 1, 2026